Iron (III) hydroxide olygoisomaltozat: a new drug for the correction of iron deficiency in patients with CKD Review
Abstract
The review discusses the correction of anemia in CKD patients with impaired renal function. Special attention is given to iron supplements, especially new drug iron (III) hydroxide olygoisomaltozat which has already been registered in Russia. Linear structure and relatively small molecular weight minimized the impact of the drug on the immune system. Matrix disposition of iron's molecules provides its slow release and very little presence of free iron in the serum, which might cause toxic effects. Iron (III) hydroxide olygoisomaltozat dose of ³1000 mg may be administered intravenously over 15 minutes without pre-infusion test dose.
About the Authors
V. M. Ermolenko
Russian medical Academy for post-graduate education, Moscow
Russian Federation
Russian Federation
N. N. Filatova
Russian medical Academy for post-graduate education, Moscow
Russian Federation
Russian Federation
References
1. Besarab A., Bolton W., Browne J. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin // N. Engl. J. Med. 1998. Vol. 339. P. 584–590.
2. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000 // Ther. Clin. Risk Manag. 2011. Vol. 7. P. 103–113.
3. Coyne D. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy // Semin. Dial. 2008. Vol. 21. P. 212–216.
4. Coyne D. The future of intravenous iron in nephrology // NDT Plus. 2011. Vol. 4. P. i6–i9.
5. Drüeke T., Locatelli F., Clyne N. et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia // N. Engl. J. Med. 2006. Vol. 355. P. 2071–2084.
6. Ford B., Coyne D., Eby C. et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management // Kidney Int. 2009. Vol. 75. 104–110.
7. Gotloib L., Silverberg D., Fudin R., Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron // J. Nephrol. 2006. Vol. 19. P. 161–167.
8. Hildebrant P., Brunn N., Nielsen O. et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfusion Alternatives in Transfusion Medicine // 2010. Vol. 11. P. 131–137.
9. Jahn M., Andreasen H., Fütterer S. et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications // Eur. J. Pharm. Biopharm. 2011. Vol. 78. P. 480–491.
10. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target // Am. J. Kidney Diseases. 2007. Vol. 50. P. 471–530.
11. Landry R., Jacobs P., Davis R. et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients // Am. J. Nephrol. 2005. Vol. 25. P. 400–410.
12. Leyland-Jones B, Semiglazov V, Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study // J. Clin. Oncol. 2005. Vol. 23. P. 5960–5972.
13. Locatelli F. Iron treatment and the TREAT trial // NDT Plus. 2011. Vol. 4. P. i3–i5.
14. Locatelli F., Aljama P., Barany P. et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure // NDT. 2004. Vol. 19. P. 1–47.
15. Macdougall I., Eckardt K., Locatelli F. Latest US KDOQI anaemia guidelines update-what are the implications for Europe? // NDT. 2007. Vol. 22. P. 2738–2742.
16. Macdougall I., Temple R., Kwan J. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial // NDT. 2007. Vol. 22. P. 784–793.
17. Nordfjeld K., Andreasen H., Thomsen L. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease // Drug. Des. Devel. Ther. 2012. Vol. 6. P. 43–51.
18. Pai A., Nielsen J.C., Kausz A. et al. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects // Clin. Pharmacol. Ther. 2010. Vol. 88. P. 237–242.
19. Parfrey P., Foley R., Wittreich B. et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease // J. Am. Soc. Nephrol. 2005. Vol. 16. P. 2180–2189.
20. Pfeffer M., Burdmann E., Chen C. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease // N. Engl. J. Med. 2009. Vol. 361. P. 2019–2032.
21. Provenzano R., Schiller B., Rao M. et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2009. Vol. 4. P. 386–393.
22. Singh A. Does TREAT give the boot to ESAs in the treatment of CKD anemia? // J. Am. Soc. Nephrol. 2010. Vol. 28. P. 1–4.
23. Singh A., Szczech L., Tang K. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease // N. Engl. J. Med. 2006. Vol. 355. P. 2085–2098.
24. Solomon S., Uno H., Lewis E. et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes // N. Engl. J. Med. 2010. Vol. 363. P. 1146–1155.
25. Spinowitz S., Kausz A., Baptista J. et al. Ferumoxytol for treating iron deficiency anemia in CKD // J. Am. Soc. Nephrol. 2008. Vol. 19. P. 1599–1605.
26. Stancu S., Bârsan L., Stanciu A. et al. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? // Clin. J. Am. Soc. Nephrol. 2010. Vol. 5. P. 409–416.
27. Strippoli G., Tognoni G., Navaneethan S. et al. Haemoglobin targets: we were wrong, time to move on // Lancet. 2007. Vol. 369. P. 346–350.
28. Szczech L., Barnhart H., Inrig J. et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes // Kidney Int. 2008. Vol. 74. P. 791–798.
29. Warady B., Seligman P., Dahl N. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients // Clin. J. Am. Soc. Nephrol. 2007. Vol. 2. P. 1140–1146.
30. Wikström B., Bhandari S., Barany P. et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease // J. Nephrol. 2011. Vol. 24. P. 589–596.
Review
For citations:
Ermolenko V.M., Filatova N.N. Iron (III) hydroxide olygoisomaltozat: a new drug for the correction of iron deficiency in patients with CKD Review. Nephrology and Dialysis. 2013;15(2):120-123. (In Russ.)
Views:
45
Email this article 